Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

- 1-32. (Canceled)
- 33. (Currently amended) A method of <u>degrading alleviating or curing</u> a prostate tumor in a mammal comprising local administration to the prostate of a composition comprising therapeutically effective concentrations of <u>eollegenase</u> <u>collagenase</u>, <u>hyaluronidase</u>, and calcium ions.
- 34. (Previously presented) The method of claim 33, wherein the composition comprises about 1 mM to about 50 mM calcium ions.
- 35. (Previously presented) The method of claim 33, wherein the calcium ions comprise a calcium salt.
- 36. (Previously presented) The method of claim 35, wherein the calcium salt comprises calcium chloride.
- 37. (Canceled)
- 38. (Currently Amended) The method of claim 33 37, wherein the composition comprises about 1 mM to about 50 mM calcium ions, about 250 to about 250,000 U/ml collagenase and about 160 to about 160,000 U/ml hyaluronidase.
- 39. (Canceled)
- 40. (Previously presented) The method of claim 33, wherein the composition further comprises an effective concentration of a nonionic surfactant.

- 41. (Currently amended) The method of claim 40, wherein the nonionic surfactant comprises an alkylphenylpolyoxethylene surfactant Triton® X-100.
- 42. (Previously presented) The method of claim 33, wherein the composition further comprises an effective concentration of an antibiotic.
- 43. (Previously presented) The method of claim 42, wherein the antibiotic comprises gentamicin sulfate.
- 44. (Previously presented) The method of claim 33, wherein local administration comprises intraprostatic injection.
- 45. (Previously presented) The method of claim 44, wherein intraprostatic injection comprises intralesional injection, transurethral injection, transrectal injection, or transperineal injection.
- 46. (Previously presented) The method of claim 44, comprising administering a single injection of about 1 to 50 ml.
- 47. (Previously presented) The method of claim 44, comprising administering a single injection of about 1 to 5 ml.
- 48. (Previously presented) The method of claim 33, wherein local administration comprises administering a depot formulation.
- 49. (Previously presented) The method of claim 33, wherein local administration comprises administering a slow release implant, a microencapsulated composition, a conjugate with a biodegradable polymer, or a conjugate with a prostate-specific immunoglobulin.
- 50. (Currently amended) A method of <u>degrading alleviating or curing</u> a prostate tumor in a mammal comprising local administration to the prostate of a sterile pyrogen-free solution

comprising effective concentrations of calcium ions, collagenase, hyaluronidase, a nonionic surfactant, an antibiotic, and a pharmaceutically acceptable aqueous carrier having a physiologic pH; wherein the solution is suitable for administration to living mammals at single or multiple dosages of about 1 to 50 ml via intraprostatic injection; and wherein administration of said solution causes the necrosis, liquification, and regression of said tumor.

- 51. (Currently amended) The method of claim 50, wherein <u>collagenase</u> is provided at a concentration of about 2,500 to 25,000 U/ml.
- 52. (Currently amended) The method of claim 50, wherein hyaluronidase is provided at a concentration of about about 1,600 to 16,000 U/ml.
- 53. (Canceled)
- 54. (Currently amended) The method of claim 50, wherein the nonionic surfactant comprises an alkylphenylpolyoxethylene surfactant Triton® X-100.
- 55. (Previously presented) The method of claim 50, wherein the antibiotic comprises gentamicin.
- 56. (Previously presented) The method of claim 50, wherein the intraprostatic injection comprises intralesional injection, transurethral injection, transrectal injection, or transperineal injection.
- 57. (Previously presented) The method of claim 50, comprising administering a single injection of about 1 to 20 ml.
- 58. (Canceled)